Abstract
In a murine model of blastoschizomycosis, amphotericin B combined with micafungin, flucytosine or voriconazole did not improve the efficacy of fluconazole. However, such combinations can constitute therapeutic options for those cases where fluconazole fails.
Publication types
-
Evaluation Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amphotericin B / therapeutic use
-
Animals
-
Antifungal Agents / therapeutic use*
-
Colony Count, Microbial
-
Disease Models, Animal
-
Drug Synergism
-
Drug Therapy, Combination
-
Echinocandins
-
Flucytosine / therapeutic use
-
Geotrichosis / drug therapy*
-
Geotrichum / drug effects*
-
Humans
-
Immunocompromised Host
-
Lipopeptides
-
Lipoproteins / therapeutic use
-
Male
-
Micafungin
-
Mice
-
Mice, Inbred Strains
-
Microbial Sensitivity Tests
-
Mycoses / drug therapy*
-
Peptides, Cyclic / therapeutic use
-
Pyrimidines / therapeutic use
-
Survival Analysis
-
Triazoles / therapeutic use
-
Trichosporon / drug effects*
-
Voriconazole
Substances
-
Antifungal Agents
-
Echinocandins
-
Lipopeptides
-
Lipoproteins
-
Peptides, Cyclic
-
Pyrimidines
-
Triazoles
-
Amphotericin B
-
Flucytosine
-
Voriconazole
-
Micafungin